I was in Paris this week in the building of the Rare Disease Alliance, an association helping patients affected by a rare disease. The association lend their space to Neovacs, a biotech company from Paris, which was organising a gathering of experts of lupus.
Lupus is one of the most common rare disease and affects more than 5 million people worldwide. This meet-up was a good opportunity for me to talk with Prf. Jean Sibilia, Head of the National Reference Centre for Systemic Autoimmune Diseases and Miguel Sieler, CEO of Neovacs which develops a drug candidate against this disease.
Learn more in the video below!Please accept preferences cookies to watch this video.
More on Neovacs in these articles from Labiotech.eu:
- Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy
- Fighting Lupus with an Autoimmune Disease Vaccine that Uses Limpet Proteins
Want to know more?